A recent JAMA Oncology study highlights the power of the open-access model GenomeDx has pursued since launching its Decipher prostate cancer prognostic.
The company has achieved even higher specificity than earlier data demonstrated, and is now building up its sales and marketing infrastructure for the planned launch of its lung cancer test.
Inflammatix hopes to market an 18-gene panel that will be able to tell from a blood sample whether a hospitalized patient has a bacterial, viral, or no infection.
A comparison of single-cell RNA sequencing profiles from more than 1,000 fresh or frozen samples suggests cryopreservation does not alter general transcriptome patterns.
The single-cell approach enabled them to identify gene expression in rare cell types, highlighting a previously unrecognized role for these cells in diabetes.
